echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medicines Company News > Innovent will announce multiple clinical data at the 2021 American Society of Clinical Oncology ASCO Annual Meeting

    Innovent will announce multiple clinical data at the 2021 American Society of Clinical Oncology ASCO Annual Meeting

    • Last Update: 2021-07-06
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Cinda Biopharmaceuticals (Hong Kong Stock Exchange stock code: 01801), a biopharmaceutical company dedicated to the development, production and sales of innovative drugs for the treatment of tumors, autoimmunity, metabolism, and ophthalmological diseases ® (sintilimab injection), pemigatinib (development code IBI375, FGFR1/2/3 inhibitor) and IBI110 (anti-LAG-3 monoclonal antibody) related clinical data will be released from June 4 to 8.
    Announced at the 2021 American Society of Clinical Oncology (ASCO) annual meeting
    .


    A brief summary is as follows:

    Oncology: Lung Cancer
    Title: Two-year follow-up results of PD-1 monotherapy for neoadjuvant treatment of non-small cell lung cancer.



    Oncology Field: Colorectal Cancer
    Title: Preliminary Results of Phase 1b Study of Sintilimab and Fruquintinib in the Treatment of Advanced Colorectal Cancer
    Report Type: Poster Discussion
    Abstract Number: 2514
    Investigators: Professor Guo Ye, Professor Li Jin (Tongji University East hospital)
    * this study Cinda biology and medicine and Huang (China) Co.


    , Ltd.
    joint cooperation


    Oncology Field: Advanced Malignant Tumor


    Tumor Field: Advanced Solid Tumor


    Report Type: Poster


    A number of independent studies related to Sintilimab are as follows:

    Oncology: Cervical Cancer


    Tumor Field: Gastric Cancer


    Title: Sintilimab combined with Anlotinib for the treatment of recurrent advanced endometrial cancer: prospective open, single-arm, phase II clinical study


    Tumor field: Non-small cell lung cancer


    Oncology field: NK/T cell lymphoma


    Oncology: Hepatocellular Carcinoma


    Tumor Field: Gastric Cancer


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.